Alvotech And Reddy’s Await US Denosumab Decision As Launch Date Closes In

Icelandic Firm’s AVT03 Rival Accepted For Review; Fresenius Kabi Just Settled Litigation

With Sandoz set to debut US competition to Prolia and Xgeva in a matter of months, other biosimilar sponsors are working hard to ensure launch of Amgen’s blockbuster in a timely manner.

Accepted_Stamp
• Source: Shutterstock

More from Biosimilars

More from Generics Bulletin